General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Innovative pricing

Price is just one of many factors affecting access to healthcare. We know that novel pricing models and generic medicines can help expand access, and both are part of our access programs.

Differential pricing for sustainable access

Differential pricing can help make medicines accessible — a treatment that is sold at full price in developed markets can be provided at a subsidized price in the poorest countries.

As part of our Malaria Initiative, Novartis provides its antimalarial medicine at not-for-profit prices for public sector use. Since 2004, thanks to economies of scale in sourcing and manufacturing, significant cost reductions were achieved, which allowed the price to be reduced by half for public-sector buyers over the years.

Novartis is a company of “firsts”: the first company to distribute its antimalarials without profit to endemic countries and the first vaccine manufacturer to create a not-for-profit vaccines research institute – the Novartis Vaccines Institute for Global Health.

Patents and licensing in least developed countries

Novartis does not enforce patents in least developed countries (LDCs). The United Nations designates these countries as highly disadvantaged in their development process, for structural, historical and geographical reasons. LDCs are also characterized by their vulnerability to external economic shocks, natural and man-made disasters and communicable diseases.

Novartis will grant non-exclusive licenses to qualified third parties to supply our patented products exclusively to LDCs.

High-quality generic medicines

Generic medicines can expand access by offering affordable treatments with the same safety and efficacy after a patent expires.

Novartis is the only major healthcare company with leadership positions in both patented and generic pharmaceuticals. Our Sandoz Division is the second-largest producer of generics, and the price points of numerous Sandoz medicines are accessible to 90% of the world’s population.

Sandoz and its affiliate 1A Pharma often compete in tenders, where the lowest price product with the best delivery conditions usually wins the contract. Sandoz and 1A Pharma have successfully tendered bids in numerous African countries.

Sandoz is the leader in biosimilarsBiosimilars are new versions of existing biopharmaceuticals whose patents have expired, with comparable safety and efficacy to the original product., which helps improve access to biopharmaceuticals after patent expiry.

Read our positions on: